Fused heterocyclic compounds

A compound and heterocyclic group technology, applied in the field of nitrogen-containing fused heterocyclic compounds, can solve problems such as low utilization value

Inactive Publication Date: 2008-04-23
TAKEDA PHARMA CO LTD
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, peptide derivatives have low utilization value as drugs from the viewpoint of pharmacokinetics, such as chemical stability and absorbability of oral administration in living organisms, bioavailability, and brain transport

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused heterocyclic compounds
  • Fused heterocyclic compounds
  • Fused heterocyclic compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0308] N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(1-propylbutyl)-1H-benzimidazol-2-amine hydrochloride

[0309]

[0310] Methyl 2-chloro-3-nitrobenzoate

[0311] A suspension of 20 g (99 mmol) of 2-chloro-3-nitrobenzoic acid in 800 mL of dichloromethane was cooled in an ice bath. Dimethylformamide (0.40 mL) was added to the reaction, followed by dropwise addition of 13.85 g (109 mmol) of oxalic acid. The reaction was allowed to warm to room temperature and stirred for 6h. Methanol (200 mL) was added dropwise and the reaction was stirred overnight. The reaction was concentrated to give a residue which was dissolved in dichloromethane and passed through a plug of silica gel eluting with a 50% ethyl acetate / hexane mixture. The filtrate was concentrated in vacuo to afford 21.5 g (100%) of the title compound.

[0312] 1 H NMR (CDCl 3 )δ3.98(s, 3H), 7.48(t, J=7.8Hz, 1H), 7.84(d, J=8.2Hz, 1H), 7.95(d, J=7.8Hz, 1H).

[0313] Methyl 2-methylamino-3-nitrobenzoate

[031...

Embodiment 8

[0341] {2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl}(4-methoxyphenyl)methyl ketone.

[0342]

[0343] 7-(4-Methoxybenzoyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one

[0344] 12 mL (6.00 mmol) of 4-methoxymagnesium bromide solution (0.5 M in THF) was diluted with 15 mL THF and cooled in an ice bath. To this solution was slowly added 309 mg (1.50 mmol) of 1-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-7-carboxylic acid methyl ester and the reaction was stirred at 60°C 24h. The reaction was quenched with water. The aqueous mixture was extracted with ethyl acetate. The extract was washed with 1N aqueous hydrochloric acid and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluting with 20-70% ethyl acetate / n-hexane, to give the title compound (148 mg, 35%).

[0345] 1 H NMR (DMSO-d 6 )δ3.00(s, 3H), 3.87(s, 3H), 6.98(d, J=8.1Hz, 1H), 7.00-7.15(m, 3H), 7.19(d, J=8.1Hz, 1H), 7.81 ...

Embodiment 9

[0354] N-(4-bromo-2-methoxy-6-methylphenyl)-4-(1-ethylbutyl)-3-methyl-3H-imidazo[4,5-c]pyridine- 2-amine

[0355]

[0356] 4-Bromo-3-methyl-1H-imidazo[4,5-c]pyridin-2(3H)-one

[0357] Heat 20.0 g (103 mmol) of 3-methyl-4-nitro-1H-imidazo[4,5-c]pyridin-2(3H)-one in 168 mL of 48% hydrobromic acid at 135 °C Solution 6h. An additional 33 mL of 48% hydrobromic acid was added and the reaction was stirred overnight at 135°C. The reaction was cooled to room temperature and quenched into 1675 mL of ice water. The resulting suspension was adjusted to pH 9 by adding 125 mL of saturated aqueous ammonia solution. The precipitate was filtered and washed with 200 mL of water and dried in a 50° C. oven under vacuum overnight to give 17.58 g (75%) of the title product as a pale yellow solid.

[0358] 1 H NMR (DMSO-d 6 ) δ 3.54 (3H, s), 7.08 (1H, d, J=4.9Hz), 7.94 (1H, d, J=4.9Hz), 11.71 (1H, s).

[0359] MS calcd: 227; found: 228 (M+H).

[0360] (E)-4-(Hex-3-en-3-yl)-3-methyl-1H-im...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

There is provided a CRF receptor antagonist comprising a compound of the formula (I) : wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; R2 is an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR3- (wherein R3 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; Y1, Y2 and Y3 are each an optionally substituted carbon or a nitrogen, provided that one or less of Y1, Y2 and Y3 is nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO2-, -NR4-, -NR4-alk-, -CONR4- or -NR4CO- (wherein alk is an optionally substituted C3.-4 alkylene and R4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; or a salt thereof or a prodrug thereof .

Description

technical field [0001] The present invention relates to novel nitrogen-containing fused heterocyclic compounds having CRF (corticotropin releasing factor) antagonistic activity and pharmaceutical compositions containing them. Background technique [0002] Corticotropin-releasing factor (hereinafter referred to as "CRF") is a neuropeptide having 41 amino acids, which is isolated and purified from the pituitary gland as a peptide that promotes the release of adrenocorticotropic hormone (ACTH). Its structure was first determined from sheep hypothalamus, and its existence was also confirmed in rats and humans and its structure was determined [Science, 213, 1394 (1981); Proc.Natl.Acad.Sci USA, 80, 4851 (1983); EMBO J. 5, 775(1983)]. The amino acid sequence is identical in human and rat, but differs by 7 amino acids in sheep. CRF is synthesized, cleaved and secreted as a carboxy-terminal prepro-CRF. CRF peptides and their mRNA are most abundant in the hypothalamus and pituitary...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D235/24C07D235/04C07D235/12C07D235/18C07D403/02
Inventor 麻生和义望月伦代艾伯特·C·吉奥科斯克里斯托弗·P·科雷特赵皙永斯科特·A·普拉特克里斯托弗·S·西德姆
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap